FluGen Inc., a
Madison biotechnology company that is developing flu vaccines, said
Tuesday it has raised $12 million in a funding round led by some of the
state’s largest investors. FluGen will use the money to continue
development and complete clinical trials for its Redee Flu vaccine that
the company says provides better coverage for the elderly and for flu
strains that have mutated from those contained in the yearly vaccine.
Read the full Milwaukee Journal Sentinel article here.